Lackner Mark 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Feb 5, 2025
Insider Transaction Report
Form 4
Lackner Mark
Chief Scientific Officer
Transactions
- Award
Common Stock
2025-02-03+335,907→ 527,224 total - Sale
Common Stock
2025-02-03$1.71/sh−14,368$24,591→ 512,856 total - Award
Stock Option (Right to Buy)
2025-02-03+124,714→ 124,714 totalExercise: $1.68Exp: 2035-02-02→ Common Stock (124,714 underlying)
Footnotes (3)
- [F1]Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
- [F2]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
- [F3]The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.